The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
First-in-human phase I trial of the dual mTORC1 and mTORC2 inhibitor AZD2014 in solid tumors.
Udai Banerji
No relevant relationships to disclose
Emma Jane Dean
No relevant relationships to disclose
Michael Gonzalez
No relevant relationships to disclose
Alastair P Greystoke
No relevant relationships to disclose
Bristi Basu
No relevant relationships to disclose
Matthew Krebs
No relevant relationships to disclose
Martina Puglisi
No relevant relationships to disclose
Lynda Grinsted
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Elisabeth Oelmann
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Wendy Burke
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Elizabeth Harrington
Employment or Leadership Position - AstraZeneca
Stephen Green
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Malcolm Ranson
Expert Testimony - Safety Review Panel